Elie Dolgin

6.7k total citations · 2 hit papers
316 papers, 4.5k citations indexed

About

Elie Dolgin is a scholar working on Molecular Biology, Public Health, Environmental and Occupational Health and Infectious Diseases. According to data from OpenAlex, Elie Dolgin has authored 316 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Molecular Biology, 39 papers in Public Health, Environmental and Occupational Health and 35 papers in Infectious Diseases. Recurrent topics in Elie Dolgin's work include Science, Research, and Medicine (28 papers), Biomedical Ethics and Regulation (25 papers) and SARS-CoV-2 and COVID-19 Research (23 papers). Elie Dolgin is often cited by papers focused on Science, Research, and Medicine (28 papers), Biomedical Ethics and Regulation (25 papers) and SARS-CoV-2 and COVID-19 Research (23 papers). Elie Dolgin collaborates with scholars based in United States, Canada and United Kingdom. Elie Dolgin's co-authors include Brian Charlesworth, Asher D. Cutter, Alison Abbott, Scott E. Baird, Michael C. Whitlock, Aneil F. Agrawal, Sarah P. Otto, Heidi Ledford, Monya Baker and Davide Castelvecchi and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Elie Dolgin

296 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The myopia boom

2015 649 citations Elie Dolgin Nature profile →
The tangled history of mRNA vaccines

2021 289 citations Elie Dolgin Nature profile →

Peers

Elie Dolgin

MB

EPIDE

RNMI

ID

GENET

Sung Sup Park South Korea

Simon J. Foote Australia

Sebastian Maurer‐Stroh Singapore

Noam Shomron Israel

Kenneth W. Dunn United States

Michael L. Metzker United States

John Bradley United Kingdom

Stephen Tomlinson United States

Ying Zhang China

Kathleen A. Kennedy United States

Sung Sup Park South Korea

Elie Dolgin

2.7k ×1.8

MB

796 ×1.1

EPIDE

362 ×0.5

RNMI

530 ×0.9

ID

1.7k ×3.0

GENET

Citations per year, relative to Elie Dolgin Elie Dolgin (= 1×) peers Sung Sup Park

Countries citing papers authored by Elie Dolgin

Since Specialization

Citations

This map shows the geographic impact of Elie Dolgin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elie Dolgin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elie Dolgin more than expected).

Fields of papers citing papers by Elie Dolgin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elie Dolgin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elie Dolgin. The network helps show where Elie Dolgin may publish in the future.

Co-authorship network of co-authors of Elie Dolgin

This figure shows the co-authorship network connecting the top 25 collaborators of Elie Dolgin. A scholar is included among the top collaborators of Elie Dolgin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elie Dolgin. Elie Dolgin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Dolgin, Elie. (2025). Dozens of new obesity drugs are coming: these are the ones to watch. Nature. 638(8050). 308–310. 5 indexed citations

2.

Dolgin, Elie. (2024). mRNA drug offers hope for treating a devastating childhood disease. Nature. 628(8007). 248–248. 2 indexed citations

3.

Dolgin, Elie. (2024). A myopia epidemic is sweeping the globe. Here’s how to stop it. Nature. 629(8014). 989–991. 7 indexed citations

4.

Dolgin, Elie. (2024). Super-resistant CAR Ts take on cancers. Nature Biotechnology. 42(1). 5–7. 1 indexed citations

5.

Dolgin, Elie. (2023). How a pioneering diabetes drug offers hope for preventing autoimmune disorders. Nature. 614(7948). 404–406. 1 indexed citations

6.

Dolgin, Elie. (2023). NASH therapies head toward landmark approval. Nature Biotechnology. 41(5). 587–590. 3 indexed citations

7.

Dolgin, Elie. (2023). A fat-blocking drug could help to fight metastatic cancer. Nature. 3 indexed citations

8.

Dolgin, Elie. (2022). Unconventional γδ T cells ‘the new black’ in cancer therapy. Nature Biotechnology. 40(6). 805–808. 8 indexed citations

9.

Dolgin, Elie. (2022). Cancer drug approvals and setbacks in 2022. Nature Cancer. 3(12). 1406–1408. 3 indexed citations

10.

Dolgin, Elie. (2021). ‘Super-antibodies’ could curb COVID-19 and help avert future pandemics. Nature Biotechnology. 39(7). 783–785. 10 indexed citations

11.

Dolgin, Elie. (2021). Drugmakers go nuclear, continuing push into radiopharmaceuticals. Nature Biotechnology. 39(6). 647–649. 15 indexed citations

12.

Dolgin, Elie. (2021). Startups set off new wave of mRNA therapeutics. Nature Biotechnology. 39(9). 1029–1031. 6 indexed citations

13.

Dolgin, Elie. (2021). Treg engineers take aim at autoimmunity. Nature Biotechnology. 39(11). 1317–1319. 9 indexed citations

14.

Dolgin, Elie. (2021). Coronavirus variant threatens global recovery. 1 indexed citations

15.

Dolgin, Elie. (2020). Synthetic biology speeds vaccine development. 1 indexed citations

16.

Dolgin, Elie. (2020). Specter of eye toxicity looms over BCMA-targeted therapy. Nature Biotechnology. 38(12). 1363–1365. 6 indexed citations

17.

Dolgin, Elie. (2020). Cancer-eating immune cells kitted out with CARs. Nature Biotechnology. 38(5). 509–511. 26 indexed citations

18.

Dolgin, Elie. (2013). Aura of mystery. Nature Medicine. 19(9). 1083–1085. 1 indexed citations

19.

Dolgin, Elie. (2013). Thanks for sharing. Nature Medicine. 19(12). 1556–1558. 3 indexed citations

20.

Dolgin, Elie. (2011). 'Game changer' antibiotic and others in works for superbug. Nature Medicine. 17(1). 10–10. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact